OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED)

CAPS Rating: 5 out of 5

Results 1 - 5 of 5

Recs

0
Member Avatar biotechf (67.94) Submitted: 7/17/2015 1:54:24 PM : Outperform Start Price: $21.43 OMED Score: +7.33

Oncomed's two most promising cancer treatments are demcizumab and tarextumab targeting difficult to treat cancers. Positive clinical trial results should give these shares a boost. Both of these drugs have partnerships: demcizumab (Celgene) and tarextumab (GSK). At $21.50 per share or about 654M market capitalization the company may increase in value if phase trial results are positive.

OncoMed is conducting two randomized Phase 2 trials of demcizumab. The YOSEMITE trial is evaluating demcizumab and gemcitabine plus Abraxane in patients with first-line metastatic pancreatic cancers. The DENALI trial will assess the efficacy of demcizumab with carboplatin and pemetrexed in first-line non-squamous NSCLC. A Phase 1b/2 trial of demcizumab and paclitaxel in patients with platinum-resistant ovarian cancer is also ongoing.

Tarextumab (anti-Notch2/3, OMP-59R5) is a novel anti-cancer stem cell antibody that prevents signaling through both the Notch2 and Notch3 receptors. Tarextumab is currently being studied in two randomized Phase 2 clinical trials. The ALPINE trial is assessing tarextumab with Abraxane plus gemcitabine in first-line advanced pancreatic cancer patients. The PINNACLE trial is testing tarextumab in combination with etoposide and cisplatin and etoposide and carboplatin in first-line extensive stage small cell lung cancer patients.

Recs

0
Member Avatar sullyz0r (87.28) Submitted: 5/28/2015 2:20:24 PM : Outperform Start Price: $23.83 OMED Score: -3.29

I'm actually not a huge fan of the "cancer stem cell" hypothesis, but I like this company a lot more for its notch/wnt pathway target pipeline.

Recs

1
Member Avatar Tophinater (30.77) Submitted: 11/17/2014 2:50:42 PM : Outperform Start Price: $20.12 OMED Score: +10.60

i don't know.

Recs

0
Member Avatar manirg (96.00) Submitted: 1/29/2014 12:07:04 PM : Outperform Start Price: $31.42 OMED Score: -45.33

High Risk but has Hugh Potential--5 to 10x. Backed by Celgene.

Recs

0
Member Avatar 5zillion (< 20) Submitted: 7/24/2013 3:40:08 PM : Outperform Start Price: $23.50 OMED Score: -27.73

Got in on tail end of this IPO and paid on the high end. Have to admit I have been biting my fingernails a little bit on this one. I do believe that with patience this one will pay off. With interest from GSK and Bayer I do believe they will be a good investment in due time.

Results 1 - 5 of 5

Featured Broker Partners


Advertisement